70849-28-4
70849-28-4
Chemical Structure
D-Allose-13C
- CAS No.: 70849-28-4
- Formula:C513CH12O6
- Molecular Weight:181.15
IUPAC Name: (2R,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexanal-1-13C
InChIKey: GZCGUPFRVQAUEE-NGBFSFADSA-N
SMILES: O=[13CH][C@@H]([C@@H]([C@@H]([C@@H](CO)O)O)O)O
Biological Activity: D-Allose-13C is the 13C labeled D-Allose (HY-128741). D-Allose exhibits antitumor activity against various cancer cells. D-Allose scavenges reactive oxygen species (ROS) and reduces oxidative stress damage. D-Allose exhibits anti-inflammatory and neuroprotective through inhibition of TLR4/PI3K/AKT signaling pathway. D-Allose exhibits antihypertensive, cryoprotective, and anti-osteoporotic activities[1][2][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
D-Allose-13C | D-Allose-13C is the 13C labeled D-Allose (HY-128741). D-Allose exhibits antitumor activity against various cancer cells. D-Allose scavenges reactive oxygen species (ROS) and reduces oxidative stress damage. D-Allose exhibits anti-inflammatory and neuroprotective through inhibition of TLR4/PI3K/AKT signaling pathway. D-Allose exhibits antihypertensive, cryoprotective, and anti-osteoporotic activities. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D-Allose (Standard) | ≥98% | D-Allose (Standard) is the analytical standard of D-Allose (HY-128741). This product is intended for research and analytical applications. D-Allose exhibits antitumor activity against various cancer cells. D-Allose scavenges reactive oxygen species (ROS) and reduces oxidative stress damage. D-Allose exhibits anti-inflammatory and neuroprotective through inhibition of TLR4/PI3K/AKT signaling pathway. D-Allose exhibits antihypertensive, cryoprotective, and anti-osteoporotic activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D-Allose-13C-2 | D-Allose-13C-2 is the 13C labeled D-Allose (HY-128741). D-Allose exhibits antitumor activity against various cancer cells. D-Allose scavenges reactive oxygen species (ROS) and reduces oxidative stress damage. D-Allose exhibits anti-inflammatory and neuroprotective through inhibition of TLR4/PI3K/AKT signaling pathway. D-Allose exhibits antihypertensive, cryoprotective, and anti-osteoporotic activities. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D-Altrose-1-13C | D-Altrose-1-13C is the 13C labeled D(+)-Altrose. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D-Allose-13C-1 | D-Allose-13C-1 is the 13C labeled D-Allose (HY-128741). D-Allose exhibits antitumor activity against various cancer cells. D-Allose scavenges reactive oxygen species (ROS) and reduces oxidative stress damage. D-Allose exhibits anti-inflammatory and neuroprotective through inhibition of TLR4/PI3K/AKT signaling pathway. D-Allose exhibits antihypertensive, cryoprotective, and anti-osteoporotic activities. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D-Allose | 99.85% | D-Allose exhibits antitumor activity against various cancer cells. D-Allose scavenges reactive oxygen species (ROS) and reduces oxidative stress damage. D-Allose exhibits anti-inflammatory and neuroprotective through inhibition of TLR4/PI3K/AKT signaling pathway. D-Allose exhibits antihypertensive, cryoprotective, and anti-osteoporotic activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Chen Z, et al., Recent research on the physiological functions, applications, and biotechnological production of D-allose. Appl Microbiol Biotechnol. 2018 May;102(10):4269-4278. [Content Brief]
- [2]. Sui L, et al., Growth inhibitory effect of D-allose on human ovarian carcinoma cells in vitro. Anticancer Res. 2005 Jul-Aug;25(4):2639-44. [Content Brief]
- [5]. Luo Y, et al., D-allose Inhibits TLR4/PI3K/AKT Signaling to Attenuate Neuroinflammation and Neuronal Apoptosis by Inhibiting Gal-3 Following Ischemic Stroke. Biol Proced Online. 2023 Nov 28;25(1):30. [Content Brief]
